GlassScriptPhysician profile
Debbie Pierce
NPI 1235744608
$6,894.92
in general payments reported to CMS, 2019-2025
20 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,446 · 2022: $1,482 · 2023: $956 · 2024: $1,459 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.54 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,732.68 | 2021-2025 | |
| Axsome Therapeutics, INC. | $673.35 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $557.18 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $546.64 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $501.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $490.96 | 2021-2024 | Caplyta |
| Lundbeck LLC | $457.75 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $442.39 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $422.73 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $277.31 | 2022-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $228.86 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $207.15 | 2024-2025 | Cobenfy |
| Indivior INC. | $122.29 | 2021-2025 | Sublocade, Perseris |
| Janssen Pharmaceuticals, INC | $108.38 | 2021-2025 | Invega Sustenna |
| Tris Pharma INC | $48.98 | 2023-2024 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.41 | 2023 | Xifaxan, Trulance |
| Pfizer INC. | $16.42 | 2024 | |
| Luye Pharma (USA) LTD. | $16.20 | 2025 | Erzofri Extended-Release |
| Braeburn INC. | $15.79 | 2024 | Brixadi |
| Phadia US INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.